Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
December 07, 2022 08:30 ET
|
Amarin Corporation plc
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 ---- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as...
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
November 15, 2022 07:00 ET
|
Amarin Corporation plc
-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for...
Amarin to Present at Jefferies London Healthcare Conference
November 09, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
November 07, 2022 08:00 ET
|
Amarin Corporation plc
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction...
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022 07:00 ET
|
Amarin Corporation plc
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales...
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
October 20, 2022 16:30 ET
|
Amarin Corporation plc
Lars Ekman and Patrick O’Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New...
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
October 20, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior...
Amarin Board of Directors Issues Statement in Response to Sarissa
October 11, 2022 16:15 ET
|
Amarin Corporation plc
-- Highlights Active Board Refreshment Process -- -- Amarin Has Engaged Proactively and Frequently with Sarissa -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amarin...
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
August 30, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
August 28, 2022 05:51 ET
|
Amarin Corporation plc
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis...